Viking Therapeutics Inc. said it is planning an underwritten public offering of common stock.
The San Diego-based biopharmaceutical company intends to grant the underwriters a 30-day option to buy up to an additional 15% of the shares in the offering.
Viking plans to use net proceeds to develop its programs called VK5211, VK0214 and VK2809 — a potential treatment for a rare genetic disease known as glycogen storage disease type Ia. Proceeds will also be used for general research and development, working capital and general corporate purposes.
William Blair & Co. LLC is acting as sole book-running manager for the proposed offering.
